KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) FCF Margin (2018 - 2025)

Moderna (MRNA) has disclosed FCF Margin for 8 consecutive years, with 131.42% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 6241.0% to 131.42% in Q4 2025 year-over-year; TTM through Dec 2025 was 106.22%, a 1429.0% decrease, with the full-year FY2025 number at 106.22%, down 1040.0% from a year prior.
  • FCF Margin was 131.42% for Q4 2025 at Moderna, up from 93.8% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 152.3% in Q1 2021 to a low of 1068.52% in Q1 2025.
  • A 5-year average of 160.11% and a median of 2.69% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 155230bps in 2021, then plummeted -63772bps in 2024.
  • Moderna's FCF Margin stood at 44.24% in 2021, then decreased by -16bps to 37.33% in 2022, then plummeted by -94bps to 2.24% in 2023, then skyrocketed by 2979bps to 69.01% in 2024, then skyrocketed by 90bps to 131.42% in 2025.
  • Per Business Quant, the three most recent readings for MRNA's FCF Margin are 131.42% (Q4 2025), 93.8% (Q3 2025), and 597.89% (Q2 2025).